

## Special Issue

# Cancer Immunotherapy: Advances and Future Prospects

### Message from the Guest Editor

In this special issue, the journal will focus on Cancer Immunotherapy, its advances and future prospects. The knowledge gained in the field of cancer immunotherapy is now being applied to unleash a robust immune response against tumors after years of painstaking research. This lead to better understand the interaction between tumors and the host immune system. However, challenges still exist in this field, includes better predicting patients response to therapy, finding targets for treatment of tumors lacking tumor-infiltrating lymphocytes also called as “immunologically cold tumors” and enhancing immunotherapy strategies by customizing immunotherapy approaches for each biological subtype. Therefore, we would like to have this special issue based on recent advances in the understanding of cancer and different immunotherapies. Adding new information on these subjects and addressing challenges and questions addressed above may lead to a better understanding of the immune response against cancer and may aid in developing cancer immunotherapies.

### Guest Editor

Dr. Sumit Agarwal

Department of Pathology, University of Alabama at Birmingham,  
Birmingham, AL 35294, USA

### Deadline for manuscript submissions

closed (31 January 2021)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/42212](https://mdpi.com/si/42212)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).